Valsartan 40 mg Tablets Recalled for Potential Labeling Errors
Aidapak Services is recalling Valsartan 40 mg tablets because they may have been mislabeled as Valsartan 80 mg or Zinc Sulfate 50 mg.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error (mislabeling) without reported illnesses or injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Aidapak Services, LLC is recalling Valsartan 40 mg tablets (NDC 00078042315) due to a labeling error. The product may have been mislabeled as Valsartan 80 mg (NDC 00078035834) or Zinc Sulfate 50 mg (NDC 00904533260). The recalled Valsartan 40 mg tablets are identified by pedigree AD52372_1 (expiration 5/17/2014) and AD32579_1 (expiration 5/9/2014).
The repacked drugs were distributed in Arizona, California, Oregon, and Washington. This recall is classified as FDA Class II, indicating a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should check their inventory for the specific NDC and pedigree codes listed above. If the product is found, it should be returned to the distributor or disposed of according to local regulations. Patients should consult their healthcare provider if they have questions regarding their medication.
The recalled product
- Product
- VALSARTAN, Tablet, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078042315.
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 90
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- VALSARTAN
- Tablet
- 40 mg has the following codes: Pedigree: AD52372_1
- EXP: 5/17/2014
- Pedigree: AD32579_1
- EXP: 5/9/2014.
Distribution
Part of a larger recall action
This product is one of 265 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 265 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-10-14
- SevereBetter Bakehouse Recalls Donutful Chocolate Dipped Vanilla Cake Donuts for Undeclared Milk
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- ModerateHalyard Laparoscopy Comprehensive Pack II Recalled for Latex Content
FDA (Devices) · 2026-10-14
Similar recalls
- ModerateDoxepin HCL Capsules Recalled for Potential Label Mixup
FDA (Drugs) · 2014-01-22
- ModerateFDA Recalls Calcium Citrate Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Irbesartan Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls Caffeine Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-22
- SevereRivaroxaban Tablets Recalled for Potential Venlafaxine Labeling Error
FDA (Drugs) · 2014-01-22
- ModerateVenlafaxine HCL Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-22